APTIVUS 250 MG
TIPRANAVIR : 250 MG · DIN 02273322 · BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Health Canada status: CANCELLED POST MARKET
What is APTIVUS?
APTIVUS 250 MG contains TIPRANAVIR : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02273322, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02273322 |
|---|---|
| Brand name | APTIVUS |
| Generic / active ingredient | TIPRANAVIR : 250 MG |
| Manufacturer | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| Strength | 250 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AE09 TIPRANAVIR |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Aug-2025 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.